Tenofovir: farmacología e interacciones
作者： Belén Sádaba , Emilio García Quetglas , José Ramón Azanza , Almudena Gómez-Giu
DOI: 10.1157/13126265
关键词:
摘要: Tenofovir es un analogo de los nucleotidos y, por ello, presenta mecanismo accion diferente al analogos a nucleosidos. Se administra via oral en forma ester disoproxil, que desesterificado para alcanzar una biodisponibilidad, supera el 20%, y aumenta ligeramente si farmaco se ingiere con grasas. Presenta distribucion tisular amplia, facilitada pequeno tamano la molecula su escasa fijacion proteinas, elimina practica totalidad activa orina, traves filtracion glomerular secrecion tubular activa. Esta circunstancia obliga realizar ajuste dosis cuando hay insuficiencia renal. De caracteristica, semivida intracelular mas 10 veces plasmatica. Su perfil farmacocinetico le configura como poco potencial producir o presentar interacciones otros farmacos. Asi, dentro antirretrovirales ha descrito aumento biodisponibilidad didanosina conlleva recomendacion utilizarlo inferior habitual, mientras puede utilizarse sin ajustes inhibidores no analogos. Tampoco parece alterar farmacocinetica farmacos proteasa, aunque estos pueden ligero tenofovir tener trascendencia clinica. senalado ausencia antirretrovirales.
elsevier.es参考文章(41)
Christophe Piketty, Anne-Marie Taburet, Corine Chazallon, Pierre-Marie Girard, Jean-Pierre Aboulker, Laurence Gérard, Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antiviral Therapy. ,vol. 12, pp. 31- 39 ,(2007)
François Raffi, Clotilde Allavena, Christophe Michau, Anne Chiffoleau, Gwenael Le Moal, Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antiviral Therapy. ,vol. 11, pp. 263- 265 ,(2006)
Brian P Kearney, John F Flaherty, Jaymin Shah, Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical Pharmacokinectics. ,vol. 43, pp. 595- 612 ,(2004) , 10.2165/00003088-200443090-00003
Jeng‐Pyng Shaw, Cathy M. Sueoka, Reza Oliyai, William A. Lee, Murty N. Arimilli, Choung U. Kim, Kenneth C. Cundy, Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharmaceutical Research. ,vol. 14, pp. 1824- 1829 ,(1997) , 10.1023/A:1012108719462
Christy Anthonypillai, JulieE Gibbs, SarahA Thomas, The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Research. ,vol. 3, pp. 1- 10 ,(2006) , 10.1186/1743-8454-3-1
Steven G. Deeks, Patricia Barditch-Crovo, Paul S. Lietman, Frances Hwang, Kenneth C. Cundy, James F. Rooney, Nicholas S. Hellmann, Sharon Safrin, James O. Kahn, Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 2380- 2384 ,(1998) , 10.1128/AAC.42.9.2380
Patrick F. Smith, Brian P. Kearney, Sandra Liaw, Denise Cloen, Julie M. Bullock, Curtis E. Haas, Kitty Yale, Brent M. Booker, Charles S. Berenson, Dion F. Coakley, John F. Flaherty, Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy. ,vol. 24, pp. 970- 977 ,(2004) , 10.1592/PHCO.24.11.970.36141
JJ Kiser, ML Carten, CL Aquilante, PL Anderson, P Wolfe, TM King, T Delahunty, LR Bushman, CV Fletcher, The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV‐infected Patients Clinical Pharmacology & Therapeutics. ,vol. 83, pp. 265- 272 ,(2008) , 10.1038/SJ.CLPT.6100269
Brian P Kearney, Kitty Yale, Jaymin Shah, Lijie Zhong, John F Flaherty, Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clinical Pharmacokinectics. ,vol. 45, pp. 1115- 1124 ,(2006) , 10.2165/00003088-200645110-00005
Johanna Weiss, Nicola Weis, Nahal Ketabi-Kiyanvash, Caroline H. Storch, Walter E. Haefeli, Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. European Journal of Pharmacology. ,vol. 579, pp. 104- 109 ,(2008) , 10.1016/J.EJPHAR.2007.11.007